journal article·2019-12-04Open access

A promising cancer diagnosis and treatment strategy: targeted cancer therapy and imaging based on antibody fragment

Xuhong Zhao, Qian Ning, Zhongcheng Mo, Shengsong Tang

Abstract

With the arrival of the precision medicine and personalized treatment era, targeted therapy that improves efficacy and reduces side effects has become the mainstream approach of cancer treatment. Antibody fragments that further enhance penetration and retain the most critical antigen-specific binding functions are considered the focus of research targeting cancer imaging and therapy. Thanks to the superior penetration and rapid blood clearance of antibody fragments, antibody fragment-based imaging agents enable efficient and sensitive imaging of tumour sites. In tumour-targeted therapy, antibody fragments can directly inhibit tumour proliferation and growth, serve as an ideal carrier for delivery of anti-tumour drugs, or manipulate the immune system to eliminate tumour cells. In this review, the excellent physicochemical properties and the basic structure of antibody fragments are expressly depicted depicted, the progress of antibody fragments in cancer therapy and imaging are thoroughly summarized, and the future development of antibody fragments is predicted.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Monoclonal and Polyclonal Antibodies Research · Glycosylation and Glycoproteins Research · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Learning Key Laboratory for Pharmacoproteomics of Hunan Province, Institute of Pharmacy and Pharmacology, University of South China

Hunan Province Key Laboratory for Antibody-Based Drug and Intelligent Delivery System, Hunan University of Medicine

Department of Histology and Embryology, Clinical Anatomy and Reproductive Medicine Application Institute, Hengyang Medical School, University of South China

Funding

National Natural Science Foundation of China · Hunan Provincial Science and Technology Plan Key Projects of China · Science and Technology Plan Key Projects of Hunan Province · the Hunan Provincial University Innovation Platform Open Fund Project · Hunan Provincial Natural Science Foundation of China

References (100+)

Show source-provided references
1. 10.1080/10717544.2018.149422410.1080/10717544.2018.1494224 ↗
2. 10.1155/2018/590647110.1155/2018/5906471 ↗
3. 10.1038/s41598-018-34967-710.1038/s41598-018-34967-7 ↗
4. 10.1016/j.pdpdt.2018.10.01610.1016/j.pdpdt.2018.10.016 ↗
5. 10.1016/j.phrs.2018.11.01410.1016/j.phrs.2018.11.014 ↗
6. 10.2217/nnm-2018-020410.2217/nnm-2018-0204 ↗
7. 10.1158/0008-5472.CAN-18-107810.1158/0008-5472.CAN-18-1078 ↗
8. 10.1007/s10637-018-0678-610.1007/s10637-018-0678-6 ↗
9. 10.1080/09205063.2016.127782810.1080/09205063.2016.1277828 ↗
10. 10.1016/j.jconrel.2017.03.00610.1016/j.jconrel.2017.03.006 ↗
11. 10.1016/S1470-2045(17)30694-010.1016/S1470-2045(17)30694-0 ↗
12. 10.1056/NEJMoa180545310.1056/NEJMoa1805453 ↗
13. 10.1056/NEJMoa181401710.1056/NEJMoa1814017 ↗
14. 10.1016/j.ejps.2018.06.01910.1016/j.ejps.2018.06.019 ↗
15. 10.1111/jcmm.1354710.1111/jcmm.13547 ↗
16. 10.1021/acs.bioconjchem.9b0023510.1021/acs.bioconjchem.9b00235 ↗
17. 10.1007/s00259-015-3038-110.1007/s00259-015-3038-1 ↗
18. 10.1158/1078-0432.CCR-18-138210.1158/1078-0432.CCR-18-1382 ↗
19. Leoh LS, Kim YK, Candelaria PV, et al. Efficacy and mechanism of antitumor activity of an antibody targeting transferrin receptor 1 in mouse models of human multiple myeloma. JI. 2018;200:3485–3494.
20. 10.1166/jbn.2015.206210.1166/jbn.2015.2062 ↗
21. 10.1021/acs.biomac.8b0050710.1021/acs.biomac.8b00507 ↗
22. 10.1016/j.tranon.2017.07.00310.1016/j.tranon.2017.07.003 ↗
23. 10.1016/j.ijpharm.2015.10.08010.1016/j.ijpharm.2015.10.080 ↗
24. 10.1016/j.molimm.2019.04.01810.1016/j.molimm.2019.04.018 ↗
25. 10.1080/19420862.2019.162446310.1080/19420862.2019.1624463 ↗
26. 10.1007/s00259-018-4214-x10.1007/s00259-018-4214-x ↗
27. 10.1016/j.cell.2018.12.00610.1016/j.cell.2018.12.006 ↗
28. 10.1016/j.antiviral.2018.12.01910.1016/j.antiviral.2018.12.019 ↗
29. 10.1016/j.ijbiomac.2018.11.20210.1016/j.ijbiomac.2018.11.202 ↗
30. 10.1186/s13045-019-0704-y10.1186/s13045-019-0704-y ↗
31. 10.1021/acs.molpharmaceut.9b0036010.1021/acs.molpharmaceut.9b00360 ↗
32. 10.1016/j.jconrel.2016.09.01910.1016/j.jconrel.2016.09.019 ↗
33. 10.1080/19420862.2017.134291410.1080/19420862.2017.1342914 ↗
34. 10.1182/blood.201887704310.1182/blood.2018877043 ↗
35. 10.1016/j.ejps.2019.04.01510.1016/j.ejps.2019.04.015 ↗
36. 10.1158/1535-7163.MCT-18-120410.1158/1535-7163.MCT-18-1204 ↗
37. 10.1016/j.molimm.2019.03.00110.1016/j.molimm.2019.03.001 ↗
38. 10.1158/1078-0432.CCR-17-312310.1158/1078-0432.CCR-17-3123 ↗
39. Kapelski S, Cleiren E, Attar RM, et al. Influence of the bispecific antibody IgG subclass on T cell redirection. MAbs. 2019;26:1–13.
40. 10.1126/scitranslmed.aau753410.1126/scitranslmed.aau7534 ↗
41. 10.3892/ijo.2015.329010.3892/ijo.2015.3290 ↗
42. 10.7150/thno.2425210.7150/thno.24252 ↗
43. 10.1186/s12951-018-0341-610.1186/s12951-018-0341-6 ↗
44. 10.1007/s11307-014-0769-510.1007/s11307-014-0769-5 ↗
45. 10.7150/thno.2767910.7150/thno.27679 ↗
46. 10.1016/j.suronc.2018.10.00410.1016/j.suronc.2018.10.004 ↗
47. 10.1158/1078-0432.CCR-14-145210.1158/1078-0432.CCR-14-1452 ↗
48. 10.1158/1078-0432.CCR-18-138210.1158/1078-0432.CCR-18-1382 ↗
49. 10.1016/j.ejmech.2018.08.01410.1016/j.ejmech.2018.08.014 ↗
50. 10.2967/jnumed.115.17130610.2967/jnumed.115.171306 ↗
51. 10.1016/j.nano.2017.06.00110.1016/j.nano.2017.06.001 ↗
52. 10.1074/jbc.RA118.00253810.1074/jbc.RA118.002538 ↗
53. 10.1021/acs.molpharmaceut.8b0100610.1021/acs.molpharmaceut.8b01006 ↗
54. 10.1021/acs.molpharmaceut.7b0096110.1021/acs.molpharmaceut.7b00961 ↗
55. 10.1021/acs.molpharmaceut.8b0095110.1021/acs.molpharmaceut.8b00951 ↗
56. 10.1007/s11307-019-01386-710.1007/s11307-019-01386-7 ↗
57. 10.1158/1078-0432.CCR-18-012310.1158/1078-0432.CCR-18-0123 ↗
58. 10.1038/s41467-018-06271-510.1038/s41467-018-06271-5 ↗
59. 10.1007/s11095-017-2096-410.1007/s11095-017-2096-4 ↗
60. 10.1007/s00262-016-1937-z10.1007/s00262-016-1937-z ↗
61. 10.1038/srep2331410.1038/srep23314 ↗
62. 10.1002/ijc.2957110.1002/ijc.29571 ↗
63. 10.1158/1078-0432.CCR-15-050310.1158/1078-0432.CCR-15-0503 ↗
64. 10.2967/jnumed.118.22356010.2967/jnumed.118.223560 ↗
65. 10.1073/pnas.150966711210.1073/pnas.1509667112 ↗
66. 10.1016/j.actbio.2018.09.02410.1016/j.actbio.2018.09.024 ↗
67. 10.1021/acs.molpharmaceut.6b0112310.1021/acs.molpharmaceut.6b01123 ↗
68. 10.1016/j.jconrel.2011.12.00710.1016/j.jconrel.2011.12.007 ↗
69. 10.1371/journal.pone.012741910.1371/journal.pone.0127419 ↗
70. 10.1016/j.nano.2015.07.00710.1016/j.nano.2015.07.007 ↗
71. 10.3390/ijms1810206410.3390/ijms18102064 ↗
72. 10.1016/j.jconrel.2015.01.02210.1016/j.jconrel.2015.01.022 ↗
73. 10.1016/j.msec.2018.04.01110.1016/j.msec.2018.04.011 ↗
74. 10.1371/journal.pone.019834710.1371/journal.pone.0198347 ↗
75. 10.1038/nbt.419510.1038/nbt.4195 ↗
76. 10.1007/s11095-016-1945-x10.1007/s11095-016-1945-x ↗
77. 10.1007/s13277-016-4803-x10.1007/s13277-016-4803-x ↗
78. 10.1080/19420862.2016.117143210.1080/19420862.2016.1171432 ↗
79. 10.7150/thno.1562910.7150/thno.15629 ↗
80. 10.18632/oncotarget.805310.18632/oncotarget.8053 ↗
81. 10.1016/j.jconrel.2016.05.02010.1016/j.jconrel.2016.05.020 ↗
82. 10.1016/j.canlet.2016.01.02710.1016/j.canlet.2016.01.027 ↗
83. 10.1007/s00253-016-7487-710.1007/s00253-016-7487-7 ↗
84. 10.1021/acs.bioconjchem.8b0066810.1021/acs.bioconjchem.8b00668 ↗
85. 10.1039/C7NR08644J10.1039/C7NR08644J ↗
86. 10.1038/srep3187810.1038/srep31878 ↗
87. 10.1002/ijc.3011910.1002/ijc.30119 ↗
88. 10.1002/adhm.20140003710.1002/adhm.201400037 ↗
89. 10.1016/j.canlet.2013.05.03510.1016/j.canlet.2013.05.035 ↗
90. 10.1016/j.biomaterials.2015.04.03010.1016/j.biomaterials.2015.04.030 ↗
91. 10.1158/1535-7163.MCT-17-104110.1158/1535-7163.MCT-17-1041 ↗
92. 10.1080/19420862.2016.125904710.1080/19420862.2016.1259047 ↗
93. 10.1111/cas.1326710.1111/cas.13267 ↗
94. 10.1021/acs.bioconjchem.8b0009110.1021/acs.bioconjchem.8b00091 ↗
95. 10.1021/acs.molpharmaceut.7b0116710.1021/acs.molpharmaceut.7b01167 ↗
96. 10.1016/j.ejpb.2016.08.01310.1016/j.ejpb.2016.08.013 ↗
97. 10.1080/21691401.2019.157788510.1080/21691401.2019.1577885 ↗
98. 10.1016/j.nano.2016.11.01810.1016/j.nano.2016.11.018 ↗
99. 10.1038/s41467-018-07582-310.1038/s41467-018-07582-3 ↗
100. 10.18632/oncotarget.2626710.18632/oncotarget.26267 ↗